Abecma Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Abecma Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Abecma market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma by targeting and eliminating malignant plasma cells. This therapy involves reprogramming the patient's own immune cells (T cells) to recognize and destroy cancer cells. The primary indications for abecma are multiple myeloma, B-cell lymphoma (BCL), and acute lymphoblastic leukemia (ALL). Multiple myeloma is a type of blood cancer that begins in the plasma cells, a type of white blood cell in the bone marrow. Abecma is used by various end users, including adults and geriatric populations, and is distributed through several channels, including hospitals, clinics, retail and specialty pharmacies, and online pharmacies.Market growth during the historic period can be attributed to the approval of Abecma for relapsed/refractory multiple myeloma, advancements in CAR T-cell therapy, the rising incidence of multiple myeloma, high efficacy in treatment-resistant cases, and increased investments in research and development.The projected growth in the forecast period is driven by the rising prevalence of multiple myeloma, expanding approved indications, advances in personalized medicine, global market expansion, and improvements in manufacturing and cost reduction. Key trends in the forecast period include greater adoption in earlier lines of treatment, geographic market expansion, technological advancements in CAR T-cell therapy, combination therapy strategies, personalized and precision medicine, and a growing focus on relapsed/refractory multiple myeloma.The rise in the prevalence of multiple myeloma is expected to drive the growth of the abecma market. Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow, and its increasing prevalence is linked to an aging population, improved diagnostic techniques, and heightened awareness of the disease.
Abecma, a CAR T-cell therapy, offers a novel treatment option by utilizing genetically modified immune cells to target and destroy cancerous plasma cells, particularly in relapsed or refractory cases. According to the American Cancer Society, in January 2024, the projected number of myeloma cases was 35,780, an increase from 34,470 in 2022, highlighting the growing demand for effective treatments like abecma. Therefore, the rise in the prevalence of multiple myeloma is a significant driver for the abecma market.A key trend in the abecma market is the focus on developing innovative treatments, particularly CAR T-cell therapy, to improve patient outcomes and expand therapeutic options for individuals with relapsed or refractory multiple myeloma. CAR T-cell therapy involves genetically engineering a patient's own T cells to better recognize and destroy cancer cells. In March 2024, Bristol Myers Squibb received European Commission approval for Abecma (idecabtagene vicleucel) to treat adult patients with relapsed and refractory multiple myeloma. This approval specifically targets patients who have undergone at least two prior therapies and have shown disease progression. This marks a major advancement in the treatment landscape for multiple myeloma.In January 2024, 2Seventy Bio Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb to expand Abecma's growth trajectory. This collaboration aims to increase access to treatment, educate healthcare providers, and potentially broaden Abecma's regulatory indications. This strategic partnership further strengthens the Abecma market, ensuring its position as a leading therapy for multiple myeloma.Key Topics Covered: 1. Executive Summary2. Abecma Market Characteristics3. Abecma Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Abecma Market Trends and Strategies5. Abecma Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Abecma Growth Analysis and Strategic Analysis Framework6.1. Global Abecma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Abecma Market Growth Rate Analysis6.4. Global Abecma Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Abecma Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Abecma Total Addressable Market (TAM)7. Global Abecma Market Pricing Analysis & Forecasts8. Abecma Market Segmentation8.1. Global Abecma Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multiple Myeloma
B-Cell Lymphoma (BCL)
Acute Lymphoblastic Luekemia (ALL)
8.2. Global Abecma Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Geriatric
8.3. Global Abecma Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals and clinics
Retail and SpecialityPharmacies
Online Pharmacies
9. Global Abecma Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Abecma Market Regional and Country Analysis10.1. Global Abecma Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Abecma Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/3chdu2
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
32 minutes ago
- Associated Press
R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry
DUBLIN--(BUSINESS WIRE)--Jul 4, 2025-- The 'Immunomodulator Therapeutics Market, Global, 2024-2030" report has been added to offering. Revenue estimate for the base year 2024 is $93 billion with a CAGR of 9.0% for the study period 2024-2030. This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting or suppressing them. It categorizes the market by modality and key indications, providing a 6-year revenue forecast for global immunomodulator prescription drugs, alongside an analysis of key industry participants. The geographic scope encompasses North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and Latin America (LATAM), with regional revenue share estimates presented on a best-effort basis. The report also discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for immunomodulator therapies, and offers competitive assessments and revenue share analyses. It examines the factors driving and restraining growth in this space, offering insights into drug development trends, partnerships, and the investment landscape. The report highlights key companies pioneering disruptive virtual care technologies and adjunctive therapies for effective disease management. Based on clinical needs, technological advancements, business models, and competitive dynamics, the report identifies the growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2024, and the forecast period is from 2025 to 2030. Growth Drivers Rising Prevalence of Autoimmune and Inflammatory Diseases Increasing prevalence of diseases like lupus, RA, Crohn's disease, and psoriasis is driving demand for immunomodulators like tumor necrosis factor (TNF) inhibitors (e.g., Humira, Remicade) and JAK inhibitors (e.g., Xeljanz). The rapidly aging global population is more susceptible to chronic autoimmune conditions. It is further bolstering demand for treatments tailored to older adults, such as more tolerable biologics. Biotech Advancements Innovations in biotech platforms and advanced modalities such as CGT, bispecific antibodies, and RNA therapies are enhancing the efficacy and safety profiles of immunomodulators and driving the development of next-gen targeted therapies. Carisma Therapeutics Inc. and Moderna, Inc. have collaborated to use Carisma's proprietary CAR-M technology and Moderna's mRNA/lipid nanoparticles (LNP) platform to develop a macrophage engineering approach for autoimmune diseases. Growing Investment in R&D Increased funding from both public and private sectors is accelerating R&D efforts for discovering new therapies and improving existing ones. The NIH allocates significant funding for research on immunomodulatory therapies, fostering innovation. An increasing number of M&A deals demonstrate a growing focus on immunology by big pharma. Success in Oncology and Expanding Applications The success of immunotherapies in oncology has raised awareness and acceptance of similar approaches in treating autoimmune and inflammatory diseases. For example, Roche's Gazyva/Gazyvaro (obinutuzumab), approved in 100 nations for several lymphoma types, is being investigated in the Phase III REGISTRY trial for lupus nephritis. Growth Restraints Immunomodulator Therapeutics: Growth Restraints, Global, 2025-2030 Stringent Regulatory Processes: Stringent regulatory processes for immunomodulatory treatment approval or the development of novel mechanisms of action, globally, can cause delays in market access and raise development expenses for pharmaceutical companies. Moreover, inadequate reimbursement/insurance coverage globally may deter wide-scale adoption, especially in public health systems or regions with limited healthcare resources. Inadequate coverage of high-cost new drugs would increase the expenses of managing long-term conditions, impacting patient compliance and market growth. Potential Adverse Effects and Safety Concerns: Immunomodulators may have serious adverse effects, such as an elevated risk of infections and autoimmune responses. For example, checkpoint inhibitor use in autoimmune disease is linked to immune-related side effects that need to be carefully managed. Adverse outcomes and safety risks may lead to regulatory actions such as market recalls, limited prescriptions, and reduced patient confidence, challenging market uptake. Patent Expiry: Expiry of blockbuster drug patents is leading to the introduction of biosimilars and generic versions, intensifying market competition, resulting in price erosions, and leading to a loss of sales revenue for branded products. For example, AbbVie's blockbuster Humira, approved for several autoimmune conditions like RA, psoriasis, Crohn's disease, and ankylosing spondylitis, started facing biosimilar competition in 2023. Patient Inconvenience: Biotech advancements have facilitated the development of effective biologic therapies; however, therapy administration requires frequent injections or infusions, making it challenging for patients to adhere to their treatment regimens. It may affect overall patient satisfaction and treatment discontinuation. The Impact of the Top 3 Strategic Imperatives on the Immunomodulator Therapeutics Industry Disruptive Technologies Why: There is an increasing incidence of autoimmune diseases, particularly impacting women. Limitations in existing therapies demand more targeted applications. Analyst Perspective: A new wave of drug classes (JAK1, IL, calcineurin, TNF?, TYK2, PDE4), across small molecules, biologics, and cell and gene therapies, will emerge, offering enhanced efficacy and safety profiles for treating autoimmune and inflammatory conditions. There will be a growing trend towards combination therapies that utilize multiple mechanisms of action to achieve better clinical outcomes. Internal Challenges Why: The industry is moving toward an extended patent cliff, with several revenue-generating blockbuster drugs like Humira and Stelara losing their exclusivity, leading to revenue losses and increased biosimilar competition, creating an urgent need for pipeline growth, and driving increased research and development (R&D). Resource demands for R&D can strain budgets, especially for smaller biotech firms. Analyst Perspective: Companies may increasingly seek strategic partnerships to share costs and risks, fostering innovation through collaborative R&D efforts. Companies that emphasize unique value propositions in these strategic alliances will be better positioned to access markets/fair pricing with drugs like JAK inhibitors and women-specific therapies. Payers will scrutinize clinical costs and patient outcomes to ensure balance and sustainable reimbursement models that reflect indication-specific needs and improve affordability. Transformative Megatrends Why: Healthcare systems are under pressure to contain current and future spending. Healthcare plan sponsors are considering their next moves as governments contemplate the impact of the Inflation Reduction Act (IRA) 2022, and associated price cuts in the United States. Analyst Perspective: Firms will invest in adaptive trial designs for evidence generation to expedite approvals for novel MoA-based targeted therapies, advancing precision medicine going forward. Pharma companies will utilize diagnostic delivery services to improve patient access by partnering with telehealth/AI-enabled symptom monitoring platforms (e.g., Ada Health) and focus on an emerging market-expansion strategy. Focus on predictive convergence of drugs and digital therapeutics will likely personalize medicine and improve experiences and outcomes. Scope of Analysis Ecosystem in the Immunomodulator Therapeutics Sector Growth Opportunity Universe in Immunomodulator Therapeutics Sector Key Competitors For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/04/2025 06:43 AM/DISC: 07/04/2025 06:43 AM
Associated Press
33 minutes ago
- Associated Press
Chiropractor Posture Correction: Colm Murph of Brighton Chiropractic Office Shares Advice in HelloNation
Brighton, N.Y., July 04, 2025 (GLOBE NEWSWIRE) -- What are the daily habits that help prevent back pain before it starts? According to Colm Murph, chiropractor and owner of Brighton Chiropractic Office, understanding how posture influences spinal health is key. In a featured article in HelloNation, Murph explains how posture correction can be a powerful preventive tool against chronic discomfort. Murph emphasizes that poor posture isn't just a momentary lapse; it can quietly erode spine health over time. Whether sitting at a desk, standing for long periods, or even scrolling on a device, small misalignments add up and place stress on muscles and joints. He outlines practical strategies for maintaining proper alignment throughout the day, such as sitting with both feet flat, standing evenly on both legs, and holding devices at eye level. These changes, while seemingly minor, support the spine's natural curve and prevent muscle fatigue and strain. Good posture, Murph explains, does more than protect against pain—it also boosts energy levels, enhances breathing, and reduces tension headaches. The key is consistency and body alignment awareness. With mindful daily posture habits, individuals can improve spinal health and reduce the risk of long-term issues. The article, Straight Talk: How Better Posture Prevents Back Pain, outlines how posture and back pain are closely connected and offers practical, chiropractor-backed advice for staying ahead of discomfort. About HelloNation HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative 'edvertising' approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities. Patrick McCabe [email protected]
Business Upturn
an hour ago
- Business Upturn
Aalborg joins Copenhagen and Aarhus in adopting cBrain's F2 Paperless Government Platform
By GlobeNewswire Published on July 4, 2025, 14:47 IST Press Release no. 05/2025 Aalborg joins Copenhagen and Aarhus in adopting cBrain's F2 Paperless Government Platform Copenhagen, July 4, 2025 cBrain (NASDAQ: CBRAIN) has signed an agreement with Aalborg Municipality, further accelerating the success of bringing the cBrain F2 Paperless Government Platform to cities and local governments. Under the agreement, cBrain will deliver F2 as a digital platform to the Urban and Rural Affairs Department in Aalborg Municipality. This administration is responsible for areas including urban development, construction, infrastructure, mobility and nature. Implementation is expected to be completed within 6–8 weeks, with a planned go-live involving 150 users by September/October 2025. Before procurement, the cBrain F2 platform underwent a comprehensive screening process to ensure alignment with Aalborg's IT architecture principles, including accessibility, secure hosting, GDPR compliance, user administration, data segmentation, scalability, and operational reliability. With this engagement, cBrain now delivers the F2 platform to the three largest municipalities in Denmark: Copenhagen, Aarhus, and Aalborg. Fully integrated and delivered out-of-the-box, cBrain F2 supports executive decision-making, formal and informal communication, case management, workflows, and compliance. Today, Copenhagen represents the largest deployment, with more than 3,000 users. The agreement with Aalborg marks an important business development for cBrain. It demonstrates that the F2 Commercial-Off-The-Shelf (COTS) Government Platform is increasingly being adopted not only by national ministries and agencies, but also by large and complex local government organizations. For the past eight years, Denmark has ranked number one in the United Nations Global E-Government Index, and the adoption of the cBrain F2 platform by the country's three largest municipalities serves as a strong international reference. This directly supports cBrain's global growth strategy. Specifically, it supports the goal of taking an international leadership position, supplying the F2 Commercial-Off-The-Shelf (COTS) platform for paperless government worldwide. Best regards Per Tejs Knudsen, CEO Inquiries regarding this Press Release may be directed to Ejvind Jørgensen, CFO & Head of Investor Relations, cBrain A/S, [email protected], +45 2594 4973 Attachment Press Release no. 2025-05 (Aalborg Urban and Rural Affairs Department Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
